Ventyx Biosciences
San Diego, California, United States · Biotechnology, Other · 82 employees
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need.
Funding history
- Funding Round — $27.0M — Sep 2024
- Funding Round — $51.0M — Sep 2021
- Funding Round — $114.3M — Jul 2021
- Funding Round — $57.3M — Mar 2021
Recent signals
- Jan 07, 2026: SEC 8-K (1.01): On January 7, 2026, Ventyx Biosciences, Inc. entered into a Material Definitive Agreement in the form of an Agreement and Plan of Merger with Eli Lilly and Company and its wholly owned subsidiary, RYLS Merger Corporation. Under the terms of the Merger Agreement, RYLS Merger Corporation will merge with and into Ventyx, resulting in Ventyx becoming a wholly owned subsidiary of Eli Lilly. This Merger has received approval from Ventyx's board of directors, and the Company's stockholders will soon vote on the adoption of the agreement at a special meeting. The strategic implication of this merger positions Ventyx within Eli Lilly's extensive operational framework, potentially enhancing its market reach and resource access.
- Sep 30, 2024: Raised $27.0M
- Sep 23, 2024: Sanofi Invests $27 Million in Ventyx Biosciences for VTX3232 Program
- May 16, 2024: Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer
- Sep 20, 2021: Raised $51.0M
- Jul 16, 2021: Raised $114.3M
- Mar 15, 2021: Raised $57.3M
See plans & pricing → Track Ventyx Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.